

2018 modafinil (generic Provigil[®]) Prior Authorization Request Page 1 of 2

(You must complete both pages.)

Fax completed form to: 1-800-639-9158 For urgent requests, please call: 1-800-551-2694

Patient information		Prescriber info	Prescriber information					
Patient name		Today's date	Physicia	Physician specialty				
Patient insurance ID	number	Physician name	<u> </u>	NPI/DEA number				
Patient address, city,	state, ZIP	Physician addre	Physician address, city, state, ZIP					
Patient home telepho	ne number	M.D. office tele	M.D. office telephone number					
Gender Male I	Patient date of birth	M.D. office fax	D. office fax number					
Diagnosis and med	cal information							
Medication requeste	ed		Frequency					
modafinil:	☐ 100 mg tablet ☐ 200 mg tablet							
New prescription O	R date therapy initiated	Quantity	Day supply	Expected length of therapy				
Diagnosis (Please check all boxes that apply and include all office notes supporting diagnosis.) ☐ Narcolepsy ☐ Obstructive sleep apnea (OSA) ☐ Shift work sleep disorder (SWSD) ☐ Other diagnosis/(ICD 10):								
Please check all boxes that apply:								
1. All covered Part D drugs on any tier of the plan's formulary would not be as effective for the enrollee as the requested formulary drug and/or would likely have adverse effects for the enrollee.								
2. Yes No Is the prescriber board certified as a sleep specialist, ear, nose and throat specialist, neurologist or pulmonologist or has obtained a consult from a board certified sleep specialist?								
3. Yes No For the treatment of a confirmed diagnosis of shift work sleep disorder (SWSD): Does the patient have a job that requires them to frequently rotate shifts or work at night and be unable to adjust to their schedule?								
4. Yes No For treatment of excessive daytime sleepiness associated with obstructive sleep apnea (OSA): Does patient have ALL of the following? If NO, complete section below:								
☐ A Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSA and meets ICSD or DSM diagnostic criteria.								
☐ Daytime t	☐ Daytime fatigue is significantly impacting, impairing, or compromising the patient's ability to function normally.							

(continued on page 2)

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. If you received this transmission in error, please notify us immediately by telephone at 1-800-551-2694.



Page 2 of 2

Ρ	lease ch	eck all bo	exes that apply (continued):							
	☐ Yes			nosis of narcolepsy documented by N	/ISLT less than 10) min or other appropriate testing?				
6.		Please complete this section only if your patient does not meet the standard requirements listed in question 2,3,4								
		and 5: Please explain why your patient should be considered for an exception although they don't meet the plan's suggested PA criteria. Statement								
		-		not met and why patient should be ex	-					
	informat	tion that is	incomplete or illegible will dela	ay the review process.)						
	-									
7			The following quentity limit	e (OL) apply to modefinity 100mg (C	OL 20 tablata na	20 days) 200mg (OL 60 tablets				
۲.	. ☐ Yes ☐ No The following quantity limits (QL) apply to modafinil: 100mg (QL 30 tablets per 30 days), 200mg (QL 60 tablets per 30 days). Does the patient require higher dosage (quantity limit exception)?									
				uested: per 30 days	= -					
	☐ The number of doses available under the dose restriction for the prescription drug has been ineffective in the treatment of the									
	enrollee's disease or medical condition.									
	☐ The number of doses available under the dose restriction for the prescription drug, based on both sound clinical evidence and medical and scientific evidence, the known relevant physical or mental characteristics of the enrollee, and known characteristics of									
				ive or adversely affect the drug's effect						
8.	☐ Pleas	se list all	medications the patient has	tried specific to the diagnosis and	specify below.					
	CURRE	NT/PAST	MEDICATIONS USED	DATES OF TREATMENT	THERAPEUTIC	OUTCOME				
g	☐ Othe	r sunnor	ting information							
٥.		☐ Other supporting information *NOTE: All exception requests require prescriber supporting statements. Additionally, requests that are subject to prior authorization (or								
	any oth	er utilizati		may require supporting information. I						
	for your	for your request.								
ī	attest that	at the med	dication requested is medically	necessary for this patient. I further at	test that the infor	mation provided is accurate and true.				
а	and that d	documenta	ation supporting this informatior	n is available for review if requested by	y the health plan	sponsor, or, if applicable, a state or				
				erson who knowingly makes or cause ates government or any state governr						
d	damages under both the federal and state False Claims Acts. See, e.g., 31 U.S.C. §§ 3729-3733. By signing this form, I represent that I have									
	obtained patient consent as required under applicable state and federal law, including but not limited to the Health Information Portability and Accountability Act (HIPAA) and state re-disclosure laws related to HIV/AIDS.									
	Prescriber signature Date									
•										

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. If you received this transmission in error, please notify us immediately by telephone at 1-800-551-2694.